Accession Number:



A POC Clinical Trial for PTSD with a First-In-Class Vasopressin 1a Receptor Antagonist

Personal Author(s):

Corporate Author:

Azevan Pharmaceuticals, Inc. Bethlehem United States

Report Date:



In this reporting period, year 2 of the project, the major milestones met included obtaining renewal from the responsible local Institutional Review Board IRB and the Human Research Protections Office HRPO and the DSMB. Patient enrollment began in year 2 with 10 patients currently randomized. In the third year of the project, the major objective will be to continue to recruit and enroll subjects to participate in the clinical study that will test the effect of SRX246, a first-in-class vasopressin 1a receptor antagonist, as a potential new treatment for PTSD.

Descriptive Note:

Technical Report,30 Sep 2016,29 Sep 2017



Subject Categories:

Communities Of Interest:

Distribution Statement:

Approved For Public Release;

File Size: